Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.51 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.51 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14872066 | 1.00 | NAAA (0.55) | NAAASMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL11990499 | 0.99 | SMN1; SMN2 (0.53) | NAAASMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL28823421 | 0.95 | SMN1; SMN2 (0.51) | NAAASMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL4761616 | 0.95 | SMN1; SMN2 (0.49) | NAAASMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL17739999 | 0.93 | NAAA (0.48) | NAAASMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL19116912 | 0.90 | HPGD (0.45) | NAAASMN1; SMN2LMNAALDH1A1THRB | |
| SCHEMBL10147986 | 0.90 | HPGD (0.45) | NAAASMN1; SMN2LMNAALDH1A1THRB | |
| SCHEMBL23347014 | 0.89 | SMN1; SMN2 (0.43) | NAAASMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL19703683 | 0.89 | SMN1; SMN2 (0.43) | NAAASMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL20936573 | 0.88 | SMN1; SMN2 (0.42) | NAAASMN1; SMN2GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2309989-B1 | DRUG LOADED POLYMERIC NANOPARTICLES AND METHODS OF MAKING AND USING SAME | BIND THERAPEUTICS INC (US) | 2016-09-07 | — | — | EP | claimed |
| US-20110064652-A1 | NANOPARTICLES FOR TARGETED DELIVERY OF ACTIVE AGENTS TO THE LUNG | BORLAK JUERGEN | 2011-03-17 | — | — | US | claimed |
| EP-2106806-A1 | Nanoparticles for targeted delivery of active agents to the lung | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. (DE) | 2009-10-07 | — | — | EP | claimed |
| EP-1996234-A2 | NANOPARTICLES FOR TARGETED DELIVERY OF ACTIVE AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2008-12-03 | — | — | EP | claimed |
| US-20080267876-A1 | Nanoparticles for Targeted Delivery of Active Agent | YISSUM RESEARCH DEVELOPMENT COMPANY (IL) | 2008-10-30 | — | — | US | claimed |
| WO-2007034479-A2 | NANOPARTICLES FOR TARGETED DELIVERY OF ACTIVE AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY (IL) | 2007-03-29 | — | — | WO | claimed |
| EP-2309989-B1 | DRUG LOADED POLYMERIC NANOPARTICLES AND METHODS OF MAKING AND USING SAME | BIND THERAPEUTICS INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20130136688-A1 | Nanoparticles for Targeted Delivery of Active Agents to the Lung | BORLAK JUERGEN (DE) | 2013-05-30 | — | — | US | disclosed |
| US-20130136688-A1 | Nanoparticles for Targeted Delivery of Active Agents to the Lung | BORLAK JUERGEN (DE) | 2013-05-30 | — | — | US | disclosed |
| US-20130136688-A1 | Nanoparticles for Targeted Delivery of Active Agents to the Lung | BORLAK JUERGEN (DE) | 2013-05-30 | — | — | US | disclosed |
| US-20110064652-A1 | NANOPARTICLES FOR TARGETED DELIVERY OF ACTIVE AGENTS TO THE LUNG | BORLAK JUERGEN | 2011-03-17 | — | — | US | disclosed |
| US-20110064652-A1 | NANOPARTICLES FOR TARGETED DELIVERY OF ACTIVE AGENTS TO THE LUNG | BORLAK JUERGEN | 2011-03-17 | — | — | US | disclosed |
| US-20110064652-A1 | NANOPARTICLES FOR TARGETED DELIVERY OF ACTIVE AGENTS TO THE LUNG | BORLAK JUERGEN | 2011-03-17 | — | — | US | disclosed |
| EP-2106806-A1 | Nanoparticles for targeted delivery of active agents to the lung | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. (DE) | 2009-10-07 | — | — | EP | disclosed |
| EP-2106806-A1 | Nanoparticles for targeted delivery of active agents to the lung | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. (DE) | 2009-10-07 | — | — | EP | disclosed |
| EP-1996234-A2 | NANOPARTICLES FOR TARGETED DELIVERY OF ACTIVE AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2008-12-03 | — | — | EP | disclosed |
| US-20080267876-A1 | Nanoparticles for Targeted Delivery of Active Agent | YISSUM RESEARCH DEVELOPMENT COMPANY (IL) | 2008-10-30 | — | — | US | disclosed |
| US-20080267876-A1 | Nanoparticles for Targeted Delivery of Active Agent | YISSUM RESEARCH DEVELOPMENT COMPANY (IL) | 2008-10-30 | — | — | US | disclosed |
| US-20080267876-A1 | Nanoparticles for Targeted Delivery of Active Agent | YISSUM RESEARCH DEVELOPMENT COMPANY (IL) | 2008-10-30 | — | — | US | disclosed |
| WO-2007034479-A2 | NANOPARTICLES FOR TARGETED DELIVERY OF ACTIVE AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY (IL) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130136688-A1 | Nanoparticles for Targeted Delivery of Active Agents to the Lung | MLEC, ALK, ICMT | NAAA 279/4885SMN1; SMN2 2068/4885GNAI3 2215/4885 |
| US-20110064652-A1 | NANOPARTICLES FOR TARGETED DELIVERY OF ACTIVE AGENTS TO THE LUNG | MLEC, ALK, ICMT | NAAA 279/4885SMN1; SMN2 2068/4885GNAI3 2215/4885 |
| US-20080267876-A1 | Nanoparticles for Targeted Delivery of Active Agent | MLEC, OGA, ILK | NAAA 100/4885SMN1; SMN2 1402/4885GNAI3 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.